GB Patent

GB0202635D0 — Formulation containing novel anti-inflammatory androstane derivative

Assigned to Glaxo Wellcome Manufacturing Pte Ltd · Expires 2002-03-20 · 24y expired

What this patent protects

A pharmaceutical composition comprising a compound of formula (I), or a solvate thereof, in combination with a muscarinic receptor antagonist.

USPTO Abstract

A pharmaceutical composition comprising a compound of formula (I), or a solvate thereof, in combination with a muscarinic receptor antagonist.

Drugs covered by this patent

azelastine-hydrochloride (AZELASTINE HYDROCHLORIDE)

Patent Metadata

Patent number: GB0202635D0
Jurisdiction: GB
Classification: —
Expires: 2002-03-20
Drug substance claim: No
Drug product claim: No
Assignee: Glaxo Wellcome Manufacturing Pte Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.